American Association for Cancer Research
Browse
00085472can083701-sup-stab_2.pdf (60.04 kB)

Supplementary Table 2 from Identification of Copy Number Abnormalities and Inactivating Mutations in Two Negative Regulators of Nuclear Factor-κB Signaling Pathways in Waldenström's Macroglobulinemia

Download (60.04 kB)
journal contribution
posted on 2023-03-30, 19:13 authored by Esteban Braggio, Jonathan J. Keats, Xavier Leleu, Scott Van Wier, Victor H. Jimenez-Zepeda, Riccardo Valdez, Roelandt F.J. Schop, Tammy Price-Troska, Kimberly Henderson, Antonio Sacco, Feda Azab, Philip Greipp, Morie Gertz, Suzanne Hayman, S. Vincent Rajkumar, John Carpten, Marta Chesi, Michael Barrett, A. Keith Stewart, Ahmet Dogan, P. Leif Bergsagel, Irene M. Ghobrial, Rafael Fonseca
Supplementary Table 2 from Identification of Copy Number Abnormalities and Inactivating Mutations in Two Negative Regulators of Nuclear Factor-κB Signaling Pathways in Waldenström's Macroglobulinemia

History

ARTICLE ABSTRACT

Waldenström's macroglobulinemia (WM) is a distinct clinicobiological entity defined as a B-cell neoplasm characterized by a lymphoplasmacytic infiltrate in bone marrow (BM) and IgM paraprotein production. Cytogenetic analyses were historically limited by difficulty in obtaining tumor metaphases, and the genetic basis of the disease remains poorly defined. Here, we performed a comprehensive analysis in 42 WM patients by using a high-resolution, array-based comparative genomic hybridization approach to unravel the genetic mechanisms associated with WM pathogenesis. Overall, 83% of cases have chromosomal abnormalities, with a median of three abnormalities per patient. Gain of 6p was the second most common abnormality (17%), and its presence was always concomitant with 6q loss. A minimal deleted region, including MIRN15A and MIRN16-1, was delineated on 13q14 in 10% of patients. Of interest, we reported biallelic deletions and/or inactivating mutations with uniparental disomy in tumor necrosis factor (TNF) receptor–associated factor 3 and TNFα-induced protein 3, two negative regulators of the nuclear factor-κB (NF-κB) signaling pathway. Furthermore, we confirmed the association between TRAF3 inactivation and increased transcriptional activity of NF-κB target genes. Mutational activation of the NF-κB pathway, which is normally activated by ligand receptor interactions within the BM microenvironment, highlights its biological importance, and suggests a therapeutic role for inhibitors of NF-κB pathway activation in the treatment of WM. [Cancer Res 2009;69(8):3579–88]

Usage metrics

    Cancer Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC